Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

Abstract: A vaginal insert controls pH within a human vagina by use of various probiotics which include lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus acidophilus, lactobacillus brevis, bifidobacterium lactis, bifidobacterium longum, lactobacillus paracasei, lactobacillus salivarius, and lactobacillus bulgaricus. In other embodiments, the use of aloe vera and aloe vera based derivatives are disclosed. Such derivatives include stabilized high molecular weight aloe vera gel polysaccharides (AVP), purified polysaccharide fractions, aloe succotrina, and aloe vera polysaccharide of Dalton weights in the range of 100,000 to 7 million. The disclosed embodiments may be applied or inserted in the form of gels, tablets, powders and other modalities.

Abstract: Disclosed herein is a novel use of a polysaccharide mixture for the treatment of hyperglycemia and/or disorders related thereto (e.g., diabetes mellitus). The polysaccharide mixture comprises about 30-50% (wt %) of ?(1?3) glucan and ?(1?6) glucan, and has a molecular weight of at least 500,000. The polysaccharide mixture may be administered to a subject suffering from hyperglycemia in a dose of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with hyperglycemia.

Abstract: A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract.

Abstract: A class of medically-effective formulations comprising cannabinoids, and terpenes, using ?-myrcene to improve effectiveness. B-myrcene decreases resistance across the blood-brain barrier for both itself and a plurality of other medically-active compounds such as other terpenes, cannabinoids, and flavonoids. Further, ?-myrcene has been determined to raise the saturation level of the cannabinoid receptor CB1 for phytocannabinoids such as delta(9)-tetrahydrocannabinol, and to increase cell membrane permeability for itself as well as cannabinoids, terpenes, flavonoids and other naturally occurring cannabis compounds, thereby improving therapeutic benefits of cannbis formulations.

Abstract: The present application relates to a method for obtaining and purifying saponins from plant extracts, through a series of salting and filtrations steps, to provide high purity saponin extracts on large scale.

Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.

Abstract: In one embodiment, synthesis of Nuxia oppositifolia nanoparticles includes providing a Nuxia oppositifolia powder; dissolving the powder in a first alcohol to provide a first alcohol extract; concentrating a filtrate from the first alcohol extract under reduced pressure to provide a dried alcohol extract; dissolving the dried alcohol extract in the first alcohol to provide a second alcohol extract; successively partitioning the second alcohol extract using n-hexane to provide an n-hexane extract; dissolving the n-hexane extract in a second alcohol and water to provide a first solution; and adding an acidic solution to the first solution to form a final solution including Nuxia oppositifolia nanoparticles.

Abstract: An enhanced smokable cannabis-based product produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, enriching the extracted oil with a formulation comprising at least purified -myrcene, and spraying the enriched oil onto dried smokable cannabis plant matter.

Abstract: The present invention provides a novel sirtuin-1 activating agent, and a formulation for suppressing cell senescence caused by oxidative stress, comprising the agent. In particular, the invention provides a sirtuin-1 activating agent consisting of a plant body or solvent extract of Peucedanum japonicum Thunb., and a formulation for suppressing cell senescence due to oxidative stress, comprising the agent.

Abstract: The invention provides a pharmaceutical composition for treating a respiratory disease, wherein the pharmaceutical composition comprises one or more components selected from picrinine, vallesamine, scholaricine, and 19-epischolaricine. The pharmaceutical composition has a good protective effect on the respiratory system, and can be used in treatment of a relevant disease.

Abstract: The present disclosure relates to the technical field of health care products and foodstuffs, in particular to a composition, a preparation method, and the use thereof in preparation of products for relieving thyroid nodules. The composition provided by the invention uses AtractylodisMacrocephalaeRhizoma and ChuanxiongRhizoma as raw materials, which show synergistic effect through rational combination. Experiments show that the composition provided by the invention can improve thyroid epithelial cell proliferation and reduce the thyroid index of thyroid nodules, and has the advantages of relieving thyroid nodules and protecting thyroid function. The invention has the advantages of simple combination, high safety, simple and easy handling and definite cure effect.

Abstract: The present invention, in some embodiments, is a composition that includes 35 to 50 weight percent of a first vegetable oil having a saturated fatty acid content of 4% to 12%, 35 to 50 weight percent of a second vegetable oil having an alpha-linolenic acid content of 45% to 65%, 0.005 to 0.15 weight percent of at least one of Vitamin A and Vitamin D, 2 to 10 weight percent of at least one phytosterol; and 0.02 to 0.2 weight percent of an antioxidant including, but not limited to, tocopherol, ascorbyl palmitate, Rosemary extract and mixtures thereof. The present invention further includes, in some embodiments, us of a composition for treating oxidative stress and cardiovascular diseases.

Abstract: The use of a poultry feed additive composition which is a flowable mixture of phytogenic compounds including at least an oil component which is microencapsulated essential thyme oil, and a saponin component which is the saponin contained in particulate dried quillaja bark powder. The mixture contains at least 0.5% saponin component (w/w), and the oil component in an effective ratio of at least 0.2:1 (w/w, oil component per saponin component), for improving the feed conversion efficiency in antibiotic-free poultry production.

Abstract: Symptoms of fibromyalgia are treated by daily administration of a regiment comprising a combination of naturally occurring ingredients selected from a group consisting of turmeric extract, boswellia extract, dandelion root, grape seed extract, green tea, a bioflavonoid complex, acetyl L-carnitine, and vitamin B12. Such ingredients are generally safe for human consumption and, when used in combination, relieve the symptoms associated with fibromyalgia.

Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.

Abstract: A method of treating cosmetic skin conditions in an individual comprising the steps of preparing a composition comprising an all-D amino acid peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E in which: A is Ser, Thr, Asn, Glu, Arg, Ile, B is Ser, Thr, Asp, Asn, C is Thr, Ser, Asn, Arg, Trp, D is Tyr, and E is Thr, Ser, Arg, or Gly and wherein all amino acids in the D peptide are the D stereoisomeric configuration and said peptide composition is administered in a cosmetically effective dose wherein said composition acts to improve the appearance of the skin. The D peptide may have a terminal amide (—NH2) or methyl ester moiety to enhance its activity and penetration into the skin.

Abstract: The present invention provides, among other things, method of treating epidermolysis bullosa including administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide. In some embodiments, the present invention also provides methods of treating a complication of epidermolysis bullosa including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.

Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.

Abstract: There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: The present invention is directed to methods of treating proteinuric diseases by the administration of av?3 integrin inhibitors.

Abstract: Methods for treating inflammation include administering to a mammal in need thereof an effective amount of a treatment composition comprising a cyclized compound of the amino acid sequence of formula I: X1-GQRETPEGAEAKPWY-X2??(I) where X1 includes an amino acid sequence with 1 to 4 members having one or more natural or unnatural amino acids selected from: C, KSP, K, ornithin, 4-amino butanoic acid, ?-alanine, 6-amino-hexanoic acid, and 7-amino-heptanoic acid; where X2 is one natural amino acid selected from: C, D, G and E; and where prior to cyclization, X1 is the N-terminus and X2 is the C-terminus.

Abstract: The invention relates to novel glycolipid compounds and pharmaceutical compositions comprising said glycolipids and to processes for preparing said glycolipids. The invention also relates to said glycolipids for use in treating tumours and methods of treating tumours using said glycolipids.

Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may then be transported to the intra-ocular region of the patient, allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness. Data assimilation methods are also disclosed, focusing on enhancing assessment of choriocapillaris and choroidal blood flow to increase sensitivity of OCT-A monitoring. The disclosed methods can be used for treatment and clinical study plans of patients with adult onset macular degeneration and related conditions.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide.

Abstract: Methods for treating sepsis of acetaminophen-induced liver damage in a subject sing a haptoglobin derivative are provided. Compositions containing a haptoglobin derivative for treating sepsis of acetaminophen-induced liver damage are provided.

Abstract: This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such as autism, schizophrenia, and dementia using the formulation.

Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.

Abstract: The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).

Abstract: This invention relates to a method for obtaining immobilized enzyme preparations, in particular to preparation and application of noval active conjugate of enzyme with a polymer carrier. Said conjugate possesses the properties of Longidaza drug and inhibits hyperplasia of connective tissue, and anti-inflammatory action, as well as it can be used for manufacturing stable, active and safe in use long-acting drugs in the form of a suppository, ointment, injection or cosmetic cream, and for making veterinary drugs. This method consists in conjugation of hyaluronidase with a water-soluble copolymer using carbodiimide or azide method.

Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.

Abstract: The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome. The invention provides a general method for treating nucleotide repeat expansion disorders and engineered nucleases suitable for practicing the method. The invention further provides vectors and techniques for delivering engineered nucleases to patient cells.

Abstract: 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed.

Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.

Abstract: A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.

Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.

Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

Abstract: The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.

Abstract: The present invention provides an injectable pharmaceutical composition containing the following components: (a) one or more kinds of peptides selected from a peptide represented by the formula (1): wherein the bond between Cys and Cys is a disulfide bond, Leu-OH shows that the C-terminal of Leu is a free carboxyl group, and other bond is a peptide bond, a peptide consisting of the amino acid sequence shown by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and salts thereof, (b) trehalose or trehalose hydrate, and (c) a pH adjuster.